Today, the global healthcare company Merck has announced that it is stopping the EPOCH study, a phase 2/3 study evaluating Verubecestat in people with mild-to-moderate Alzheimer’s disease.
from Dementia Big http://ift.tt/2kyC0SJ via alcoholic dementia
http://ift.tt/2kyDWdW
No comments:
Post a Comment